Want to see JP:4883 full AI Analyst Report?
Top Page
Modalis Therapeutics Corporation
(4883)
Select Model
Select Model
Rating:41Neutral
Price Target:
¥32.00
▼(-42.86% Downside)
Action:Reiterated
Date:06/26/26
The score is primarily weighed down by weak financial performance (minimal revenue, large recurring losses, and sustained cash burn) and bearish technical trends (price below key moving averages with negative MACD). Valuation provides little offset because earnings are negative (negative P/E) and no dividend yield is available.
Positive Factors
Low reported debt
Balance-sheet leverage is conservative with no reported debt in 2024–2025. This durable advantage reduces mandatory interest costs and refinancing pressure, giving management more optionality to pursue partnerships or staged R&D funding before taking on leverage.
Negative Factors
Persistent cash burn
Operating and free cash flows are consistently and materially negative, with burn accelerating in 2025. This structural cash outflow creates ongoing financing needs, increases dilution or partnership dependence, and heightens execution risk if capital markets tighten or partner deals slow.
Read all positive and negative factors
Positive Factors
Negative Factors
Low reported debt
Balance-sheet leverage is conservative with no reported debt in 2024–2025. This durable advantage reduces mandatory interest costs and refinancing pressure, giving management more optionality to pursue partnerships or staged R&D funding before taking on leverage.
Read all positive factors
Modalis Therapeutics Corporation (4883) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥3.21B
Dividend YieldN/A
Average Volume (3M)719.68K
Price to Earnings (P/E)―
Beta (1Y)0.04
Revenue GrowthN/A
EPS Growth14.26%
CountryJP
Employees14
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-24.01
Shares Outstanding97,334,100
10 Day Avg. Volume617,120
30 Day Avg. Volume719,680
Financial Highlights & Ratios
PEG Ratio0.81
Price to Book (P/B)1.55
Price to Sales (P/S)0.00
P/FCF Ratio-2.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-22.2
Revenue Forecast (FY)¥800.00M
Modalis Therapeutics Corporation Business Overview & Revenue Model
Company Description
Modalis Therapeutics Corporation focuses on discovering and developing treatments for severe genetic conditions. The company utilizes its proprietary CRISPR-GNDM technology to create therapies by controlling gene expression through the epigenetic ...
How the Company Makes Money
null...
Modalis Therapeutics Corporation Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
54
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 40.50M | 1.10M |
| Gross Profit | -583.00K | 0.00 | 0.00 | -731.00K | -83.17M | 1.10M |
| EBITDA | -2.33B | -2.21B | -2.15B | -2.37B | -2.58B | -667.55M |
| Net Income | -1.56B | -2.15B | -1.32B | -2.39B | -2.70B | -738.96M |
Balance Sheet | ||||||
| Total Assets | 3.42B | 2.96B | 3.69B | 2.03B | 3.13B | 6.07B |
| Cash, Cash Equivalents and Short-Term Investments | 3.26B | 2.81B | 3.58B | 1.88B | 2.93B | 4.94B |
| Total Debt | 0.00 | 0.00 | 0.00 | 412.50M | 0.00 | 0.00 |
| Total Liabilities | 228.82M | 170.94M | 143.47M | 645.50M | 188.60M | 519.92M |
| Stockholders Equity | 3.19B | 2.79B | 3.55B | 1.38B | 2.94B | 5.55B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -2.12B | -1.43B | -2.29B | -2.09B | -854.58M |
| Operating Cash Flow | 0.00 | -2.12B | -1.43B | -2.25B | -1.90B | -747.47M |
| Investing Cash Flow | 0.00 | -2.57M | -188.00K | -39.70M | -185.72M | 171.56M |
| Financing Cash Flow | 0.00 | 1.35B | 3.04B | 1.22B | 63.68M | 72.63M |
Modalis Therapeutics Corporation Technical Analysis
Negative
56.00
Price Trends
48.06
Negative
52.55
Negative
61.05
Negative
Market Momentum
-4.21
Negative
35.83
Neutral
60.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4883, the sentiment is Negative. The current price of 56 is above the 20-day moving average (MA) of 33.75, above the 50-day MA of 48.06, and below the 200-day MA of 61.05, indicating a bearish trend. The MACD of -4.21 indicates Negative momentum. The RSI at 35.83 is Neutral, neither overbought nor oversold. The STOCH value of 60.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4883.
Modalis Therapeutics Corporation Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ¥13.87B | 25.98 | ― | ― | 1.62% | -25.43% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥5.60B | 28.29 | ― | 3.21% | 1.60% | -32.57% | |
48 Neutral | ¥5.58B | -6.18 | ― | ― | 246.42% | 9.39% | |
42 Neutral | ¥7.10B | -7.37 | -90.96% | ― | 24.62% | 60.41% | |
41 Neutral | ¥3.21B | -1.45 | ― | ― | ― | 14.26% | |
41 Neutral | ¥5.42B | -0.67 | ― | ― | -39.73% | -9.00% |
* Healthcare Sector Average
JP:4883
Modalis Therapeutics Corporation
33.00
-48.00
-59.26%
JP:4597
Solasia Pharma KK
26.00
-11.00
-29.73%
JP:4539
Nippon Chemiphar Co., Ltd.
1,550.00
77.92
5.29%
JP:4574
Taiko Pharmaceutical Co., Ltd.
277.00
-7.00
-2.46%
JP:4582
Symbio Pharmaceuticals Limited
71.00
-97.00
-57.74%
JP:4892
Cyfuse Biomedical K.K.
553.00
-124.00
-18.32%
Modalis Therapeutics Corporation Corporate Events
Modalis Books ¥14 Million in FX Gains, Boosting Quarterly Results
May 13, 2026
Modalis Therapeutics Corporation reported non-operating income of 14 million yen in foreign exchange gains for the three months ended March 31, 2026, driven primarily by the revaluation of its foreign currency-denominated assets and liabilities am...
Modalis outlines conditions and limitations around its Q1 2026 disclosure
May 13, 2026
Modalis Therapeutics has released its business and financial report for the first quarter of 2026, providing an update on its operations and corporate status. The document is positioned as an informational, reference-only English translation of th...
Modalis Narrows Quarterly Loss but Keeps Outlook Uncertain Amid Zero Revenue
May 13, 2026
Modalis Therapeutics reported no operating revenue for the quarter ended March 31, 2026, and narrowed its loss attributable to owners of the parent to ¥323 million from ¥652 million a year earlier. Basic loss per share improved to ¥...
Modalis Sells Idle U.S. Equipment, Books Extraordinary Gain on Asset Transfer
Apr 27, 2026
Modalis Therapeutics’ U.S. subsidiary in Waltham, Mass., has decided to transfer machinery and equipment that have become idle following the completion of their intended roles in process development, as part of a broader effort to improve ma...
Modalis Sets Terms for 18th Stock Option Plan, Issuing 935,000 Potential Shares
Apr 14, 2026
Modalis Therapeutics has set the detailed terms for its 18th stock option program, confirming an exercise price of 6,100 yen per unit, equivalent to 61 yen per share, calculated as the higher of a 5% premium over the prior month’s average cl...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.